Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 23, 2024
Context: This filing reports on the progress of a share repurchase programme initiated on August 7, 2024, under the EU Market Abuse Regulation (MAR) Safe Harbour Rules. Novo Nordisk is a global healthcare company focused on defeating serious chronic diseases, employing approximately 69,000 people across 80 countries.
Key Financial Metrics
This filing focuses on capital allocation activities rather than operational financial performance. The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the period.
| Metric | Value |
|---|---|
| Total Share Repurchase Programme Cap | DKK 20 billion |
| Programme Period | 12 months beginning February 6, 2024 |
| Specific Sub-programme Cap (Aug 7 - Nov 4, 2024) | DKK 2.4 billion |
| Total B Shares Repurchased (Since Feb 6, 2024) | 12,465,249 shares |
| Average Purchase Price (Since Feb 6, 2024) | DKK 881.62 per share |
| Total Transaction Value (Since Feb 6, 2024) | DKK 10,989,557,516 |
| Treasury Shares Held | 13,793,880 B shares (0.3% of share capital) |
Material Changes
The filing details specific repurchase transactions executed between September 16 and September 20, 2024, following a previous announcement on September 16. The accumulated transaction value under the specific August 7 programme reached DKK 1,261,851,466 as of September 20, 2024.
- Recent Activity: 230,000 B shares were purchased between September 16 and September 20, 2024.
- Price Range: Recent average purchase prices ranged from DKK 877.09 to DKK 927.02.
- Accumulation: Total shares repurchased under the specific August programme increased from 1,168,123 to 1,398,123.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme cap of DKK 20 billion during the 12-month period starting February 6, 2024. As of September 20, 2024, approximately DKK 11.0 billion of the DKK 20 billion cap has been utilized.
Risks and Contingencies: The filing does not disclose new operational risks or contingencies. It notes that transaction details are published on the company website and that the repurchases are conducted in compliance with EU regulations.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 20 billion share repurchase programme (approx. DKK 9 billion remaining as of Sept 20).
- Confirm the current treasury share count (13,793,880 B shares) against the total share capital of 4,465,000,000 shares.
- Monitor the average purchase price trend (DKK 881.62 average) relative to current market prices to assess capital efficiency.
- Check the company website (novonordisk.com) for daily transaction details as referenced in the filing.